首页> 外文期刊>Clinical transplantation. >Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis.
【24h】

Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis.

机译:肝移植前经肝动脉化疗栓塞在肝细胞癌中的作用,并特别考虑肿瘤坏死。

获取原文
获取原文并翻译 | 示例
           

摘要

Several authors suggest that local ablative therapies, specifically transarterial chemoembolization (TACE), may control tumor progression of hepatocellular carcinoma (HCC) in patients who are on the waiting list for liver transplantation (orthotopic liver transplantation, OLT). There is still no evidence if TACE followed by OLT is able to prevent recurrence of tumor, to prolong survival rate of the patients on the waiting list, or to improve the survival after OLT. We report 27 patients with HCC who underwent OLT. From these patients, 15 were pre-treated with TACE alone or in combination with percutaneous ethanol injection (PEI) or laser-induced thermo therapy (LITT). Mean time on the waiting list was 214 d for treated patients and 133 d for untreated patients. Comparing pre-operative imaging and histopathological staging post-transplant, we found 13 patients with tumor progression out of which five were treated with TACE. In two of the TACE patients a decrease of lesions could be achieved. In a single patient, there was no evidence of any residual tumor. Only one patient displayed tumor progression prior to OLT despite undergoing TACE. Comparison of outcome in patients undergoing TACE or having no TACE was not statistically significant (p = 0.5). In addition, our analysis showed that progression either in the total study population or in the TACE group alone is associated with a significant poorer outcome concerning overall survival (p = 0.02 and p = 0.02).
机译:几位作者建议,对于正在等待肝移植(原位肝移植,OLT)的患者,局部消融疗法(特别是经动脉化学栓塞术(TACE))可以控制肝细胞癌(HCC)的肿瘤进展。尚无证据表明TACE + OLT能够预防肿瘤复发,延长候诊患者的生存率或提高OLT术后生存率。我们报告了27例接受OLT的HCC患者。这些患者中,有15位接受了单独或联合经皮乙醇注射(PEI)或激光诱导热疗法(LITT)的TACE预处理。在等待名单上的平均时间是治疗患者为214 d,未治疗患者为133 d。比较术前影像学和移植后的组织病理学分期,我们发现13例肿瘤进展的患者,其中5例接受了TACE治疗。在两名TACE患者中,可以减少病变。在单个患者中,没有任何残留肿瘤的证据。尽管接受TACE,但只有一名患者在OLT之前显示出肿瘤进展。进行TACE或不进行TACE的患者的结局比较无统计学意义(p = 0.5)。此外,我们的分析表明,无论是在总体研究人群中还是仅在TACE组中,进展都与总体生存率显着较差有关(p = 0.02和p = 0.02)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号